🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Borderline-resectable Pancreatic Cancer

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer NCT07705919Phase 1, Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fluorouracil, Gadoli… Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC NCT06714604Phase 31 site📍 Gothenburg Sahlgrenska University Hospital · Tests: FOLFIRINOX or gemcitabine-nab-paclitaxel, FOLFIRINOX or gemcitabine-nab-paclitaxel Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer NCT07539155Phase 1, Phase 21 site📍 Little Rock University of Arkansas · Tests: Intratumoral MMR Injection Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial) NCT05298722NA8 sites📍 Ghent📍 Dendermonde📍 Eeklo University Hospital, Ghent · Tests: Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires. Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) NCT06384560Phase 1, Phase 24 sites📍 Amsterdam📍 Maastricht📍 Nieuwegein Amsterdam UMC, location VUmc · Tests: Pembrolizumab, Folfirinox, SABR Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment NCT06574620NA1 site📍 Vancouver British Columbia Cancer Agency · Tests: Genetic testing, Optional biopsy, Tissue collection Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas NCT02598349Phase 24 sites📍 Little Rock📍 Jacksonville📍 Warrenville Proton Collaborative Group · Tests: Proton Radiation, Capecitabine, Surgical resection DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer NCT06173310NA2 sites📍 Indianapolis📍 Columbus Ohio State University · Tests: Point-of-care Portable Perfusion Phantom (P4) Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer NCT07436741Phase 31 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: surufatinib + gemcitabine + nab-paclitaxel, gemcitabine + nab-paclitaxel Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source NCT02843945Phase 1, Phase 26 sites📍 Tampa📍 Chicago📍 Oak Lawn CivaTech Oncology · Tests: Directional Brachytherapy Source Implant Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach NCT05764720NA4 sites📍 Birmingham📍 Duarte📍 St Louis Varian, a Siemens Healthineers Company · Tests: Daily Adaptive External Beam Radiation Therapy Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer NCT07645651Phase 11 site📍 Seattle University of Washington · Tests: Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy, Biospecimen Collection Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer NCT06423326Phase 22 sites📍 Washington D.C.📍 Atlanta Georgetown University · Tests: Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer NCT06944587n/a5 sites📍 Bergen📍 Stavanger📍 Tromsø Oslo University Hospital · Tests: Chemotherapy, Radiology, Pancreatectomy, Endoscopy Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma NCT05083247Phase 210 sites📍 Antwerp📍 Brussels📍 Brussels Erasme University Hospital · Tests: mFOLFIRINOX or Gemcitabine nab-paclitaxel, Isotoxic High-Dose (iHD)-SBRT, Surgery PULSAR in Systemic Therapy for Pancreatic Cancer NCT07269626Phase 21 site📍 Seoul Samsung Medical Center · Tests: Personalized Ultrafractionated Adaptive Radiotherapy Stereotactic Magnetic Resonance Guided Radiation Therapy NCT04115254NA2 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: MR-guided Linac Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer NCT05356039n/a1 site📍 Umeå Umeå University 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC NCT07043270Phase 21 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: Nab-paclitaxel + Gemcitabine, modified FOLFIRINOX (mFOLFIRINOX) Targeted Pathway Inhibition in Patients With Pancreatic Cancer NCT04005690EARLY Phase 11 site📍 Portland OHSU Knight Cancer Institute · Tests: Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer NCT06944106Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: AK112 Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer NCT06435260Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Camrelizumab+chemotherapy, hypofractionated radiotherapy Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy NCT06595160n/a1 site📍 Atlanta Emory University · Tests: Non-Interventional Study HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation NCT07240766Phase 22 sites📍 Hangzhou📍 Hangzhou Zhejiang University · Tests: HRS-4642+AG+Nimotuzumab Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma NCT05241249Phase 21 site📍 New York Susan E. Bates · Tests: Bethanechol, Gemcitabine, nab-paclitaxel AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer NCT07619313Phase 11 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biopsy Procedure, Cisplatin, Computed Tomography, Durvalumab, Fluorouracil The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer NCT05802394NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: Later-line therapy A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer NCT07671339Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: ELI-002 7P, Tislelizumab, mFOLFIRINOX Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer NCT04894643NA2 sites📍 Wiener Neustadt📍 Wiener Neustadt EBG MedAustron GmbH · Tests: Proton Ions, Nab-PACLitaxel, Gemcitabine, Capecitabine, Surgical resection of the pancreas (when feasible) PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017Phase 19 sites📍 Newport Beach📍 Miami📍 Detroit PanTher Therapeutics · Tests: PTM-101
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy